The VJSessions have brought together leading experts virtually to help continue the valuable international collaborations in diseases such as Multiple Myeloma, CLL, AML, Lymphoma, MDS and MPNs. You can view our collection of webinar sessions below at your convenience, as well as being able to listen to podcasts of each session on the go.
![Multiple Myeloma](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101837/MM-section-Header.jpg)
Multiple Myeloma
Roundtable Discussions from IBC 2024
Key highlights from EHA 2023
iwMyeloma 2023
Key highlights from ASH 2022
Updates from IMS 2022
Myeloma updates from EHA 2022
Myeloma treatment in the UK
iwCAR-T 2022 day 3 highlights with a focus on myeloma
PIKfyve, RAS, the epigenome & PROTAC therapy
Day 1 highlights from Myeloma 2022
Day 2 highlights from Myeloma 2022
T-Cell engagers
Novel targets in 2022
Using single-cell analysis to tackle myeloma
Genomics in the age of I-O
Post-ASH 2021
A deep dive into screening for precursor conditions
Post-EHA/ASCO 2021
The patient perspective
Post-COMy 2021
Post-ASH 2020
Post-ASH 2020 UK
Myeloma & COVID-19
COMy & EHA 2020
![Chronic Lymphocytic Leukemia (CLL)](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101837/CLL-section-Header.jpg)
Chronic Lymphocytic Leukemia (CLL)
Updates in the treatment of CLL from EHA 2024
Roundtable Discussions from IBC 2024
Updates in BTK inhibitors from EHA 2023
Key highlights from ASH 2022
Key highlights from SOHO 2022
CLL updates from iwCAR-T 2022
Exploring key ASH 2021 clinical trials in the frontline and R/R setting
Post-EHA/ICML 2021
Post-ASH 2020
ASCO & EHA 2020
![Acute Myeloid Leukemia (AML)](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101837/AML-section-Header.jpg)
Acute Myeloid Leukemia (AML)
iwAL 2023
Improving transplantation outcomes in AML
iwAL 2022
AML updates from iwCAR-T 2022
Updates in FLT3+ from ASH 2021
Post-EHA/ASCO 2021
Post-ASH 2020
FLT3-Mutated AML
Venetoclax-Based Regimens
IDH Inhibitors
Immunotherapy
EHA & ASCO 2020
![Myelodysplastic Syndromes (MDS)](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101837/MDS-section-Header.jpg)
Myelodysplastic Syndromes (MDS)
Novel developments in lower-risk MDS & important practical considerations when treating patients
The i4MDS consortium and immune monitoring in MDS
Treating lower-risk MDS beyond ESA failure
Treating lower-risk MDS: practical management of anemia
TP53 mutation in MDS
Novel agents being explored in lower- and higher-risk MDS
Roundtable discussions from IBC 2024
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS
Comparing the ICC and WHO classifications for MDS & their impact on clinical practice
Key highlights from ASH 2022
iwMDS 2022
The impact of AI in MDS
What did ASH 2021 mean for MDS?
Post-EHA/ASCO 2021
Women in Science
Giants in MDS
Diagnosis & Prognosis
Global Perspectives
Post-ASH 2020
Lower-Risk Disease
Latest Updates
![Myeloproliferative Neoplasms (MPNs)](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101837/MPNs-section-Header.jpg)
Myeloproliferative Neoplasms (MPNs)
Key highlights from ASH 2023
Key highlights from ASH 2022
Key updates from the 2022 Texas MPN Workshop
Key updates from EHA 2022
Key updates from ASH 2021
Post-EHA/ASCO 2021
Post-ASH 2020
2020 Texas MPN Workshop
![Lymphoma](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101837/Lymphoma-section-Header.jpg)
Lymphoma
Roundtable discussions from IBC 2024
iwNHL 2023
Updates in CAR-T & bispecific antibodies from EHA 2023
Key highlights in T-cell lymphoma from ASH 2022
Key highlights in NHL from ASH 2022
iwNHL 2022
Key updates in lymphoma and impact on UK clinical practice
Lymphoma updates from iwCAR-T 2022
CAR-T and lymphoma treatment in the UK
Post-ASH 2021
Post-EHA/ICML 2021
Post-ASH 2020 UK
Post-ASH 2020
![Amyloidosis](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101836/Amyloidosis-section-Header.jpg)
Amyloidosis
Highlights from ASH 2023
Updates in diagnosis, available therapies and the multidisciplinary team
Highlights from ISA 2022
![General Hematology](https://d36dxcsn6kza9w.cloudfront.net/wp-content/uploads/2023/03/12101836/General-Hematology-section-Header.jpg)